acromegaly/triglyceride

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 84 resultat

Effect of octreotide pretreatment on surgical outcome in acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Pretreatment with octreotide (OCT) in acromegaly has been reported to improve surgical outcome. The objective of this study was to analyze retrospectively the effects of a 3- to 6-month presurgical treatment with OCT in acromegalics focusing on electrocardiographic (ECG) records, blood pressure

Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The effectiveness and short-term safety of recombinant human GH (r-hGH) in acromegaly patients with GH deficiency (GHD) after treatment are not well established. The study includes ten subjects with acromegaly who had GHD treated with r-hGH for 6 months. Control groups consisted of ten age-,

Association of total, acylated and unacylated ghrelin with apolipoprotein A1 and insulin concentrations in acromegalic patients.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Ghrelin is a hormone that occurs in acylated (AG) or unacylated (UG) form. Ghrelin strongly stimulates growth hormone (GH) secretion from anterior pituitary, as well as regulates the energy balance and various metabolic parameters. Increased consideration is given to UG, thought to be

Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Acromegalic patients have increased lipolysis and decreased fat mass as well as reduced insulin sensitivity and glucose intolerance. During somatostatin analog therapy, these changes persist despite GH suppression, but they are now due to drug-induced suppression of insulin secretion. By

Carbohydrate tolerance and serum lipids in acromegaly before and during treatment with high dose octreotide.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Carbohydrate tolerance and serum lipids were studied in 14 patients with acromegaly before and in response to treatment with high dose somatostatin analogue (octreotide) over a 14-week period. Patients were assessed with respect to growth hormone (GH) profile, IGF1, HbA1, fasting lipids, and the GH,

Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Impaired glycaemic control, characteristic of acromegaly, can be exacerbated by treatment with somatostatin analogues (SSAs), particularly those with multireceptor activity. We present data from the PRIMARYS study on the impact of the SSA lanreotide, associated with tumour volume and

Elevated fibrinogen levels decrease following treatment of acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Acromegaly is associated with increased morbidity and mortality from cardiovascular disease and from stroke in particular. Fibrinogen is an established risk factor for stroke and myocardial infarction and high levels of plasminogen activator inhibitor-1 (PAI-1) activity were predictive of

Effects of acromegaly treatment and growth hormone on adipose tissue lipoprotein lipase.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Lipoprotein lipase (LPL) hydrolyzes lipoprotein triglyceride into nonesterified fatty acids, which are then reesterified and stored in adipose tissue. Previous studies have demonstrated increases in LPL in response to insulin-like growth factor I and GH when added in vitro. This study examined the

IGF(CA)19 and IGFBP-3-202A/C gene polymorphism in patients with acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE We aimed to investigate IGF-1 and IGFBP-3 gene polymorphisms in patients with acromegaly. METHODS We included 34 patients with acromegaly and 37 healthy subjects to study. At baseline examinations, antropometric measurements were done. Genomic DNA from the patients and controls were

Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Untreated acromegaly is associated with an increased cardiovascular morbidity and mortality. The contribution of altered lipid metabolism remains unclear. We investigated the relationship between serum apolipoprotein(a) (apo(a)) and growth hormone (GH) levels in 15 patients with acromegaly before

Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Both growth hormone (GH) excess and GH deficiency are associated with abnormalities in body composition and biomarkers of cardiovascular risk in patients with pituitary disorders. However, the effects of developing GH deficiency after definitive treatment of acromegaly are largely

The atherogenic plasma remnant-like particle cholesterol concentration is increased in the fasting and postprandial state in active acromegalic patients.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Premature atherosclerosis is a clinical feature in untreated acromegaly. Increased postprandial lipoprotein remnant levels are associated with premature atherosclerosis. In most studies, remnants have been measured indirectly using retinyl esters (RE) as a chylomicron core label. Remnants

Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Although epidemiological studies have found that GH and IGF-1 normalization reduce the excess mortality of active acromegaly to expected rates, cross-sectional data report some cardiovascular (CV) risk markers to be less favorable in remission than active acromegaly. OBJECTIVE The

Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND Patients with acromegaly have an increased morbidity and mortality for cardiovascular diseases. Despite the increasing evidence for the existence of a specific cardiomyopathy in acromegaly, the presence of vascular abnormalities has been never investigated. OBJECTIVE To evaluate the

Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Complete remission of acromegaly is associated with favourable changes in cardiovascular risk parameters. We evaluated the effects of suboptimal therapy on haemodynamic, metabolic, inflammatory and coagulation cardiovascular risk indices. METHODS Eighteen acromegalic patients on

Tidigare
1
2
3
4
5
6
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning